<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81334</article-id><article-id pub-id-type="doi">10.7554/eLife.81334</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Protease Inhibitors</subject></subj-group></article-categories><title-group><article-title>Developing evolution-resistant drugs for COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-6442"><name><surname>Weinreich</surname><given-names>Daniel M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1424-7541</contrib-id><email>daniel_weinreich@brown.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Daniel M Weinreich</bold> is in the Department of Ecology, Evolution and Organismal Biology, and the Center for Computational Molecular Biology, Brown University, Providence, United States</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Department of Ecology, Evolution and Organismal Biology, Brown University</institution></institution-wrap><addr-line><named-content content-type="city">Providence</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Center for Computational Molecular Biology, Brown University</institution></institution-wrap><addr-line><named-content content-type="city">Providence</named-content></addr-line><country>United States</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>26</day><month>07</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e81334</elocation-id><permissions><copyright-statement>© 2022, Weinreich</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Weinreich</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81334-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/elife.77433" id="ra1"/><abstract><p>Analyzing how mutations affect the main protease of SARS-CoV-2 may help researchers develop drugs that are effective against current and future variants of the virus.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Mpro</kwd><kwd>SARS-CoV-2</kwd><kwd>deep mutational scanning</kwd><kwd>main protease</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>S. cerevisiae</italic></kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Analyzing how mutations affect the main protease of SARS-CoV-2 may help researchers develop drugs that are effective against current and future variants of the virus.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Flynn JM, Samant N, Schneider-Nachum G, Bakan DT, Yilmaz NK, Schiffer CA, Moquin SA, Dovala D, Bolon DNA. 2022. Comprehensive fitness landscape of SARS-CoV-2 M<sup>pro</sup> reveals insights into viral resistance mechanisms. <italic>eLife</italic> <bold>11</bold>:e77433. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/elife.77433">10.7554/elife.77433</ext-link>.</p></boxed-text><p>As of mid-July 2022, more than 12 billion doses of vaccines against SARS-CoV-2, the virus responsible for COVID-19, have been administered to over 5 billion individuals (<xref ref-type="bibr" rid="bib13">WHO, 2022</xref>). However, mutations that allow the virus to evade vaccines are spreading globally, leading to a need for boosters and updated vaccines (<xref ref-type="bibr" rid="bib1">Callaway, 2021</xref>; <xref ref-type="bibr" rid="bib12">Vogel, 2022</xref>). This immunity ‘arms race’ illustrates how efforts to control the COVID-19 pandemic could benefit from additional pharmaceutical approaches.</p><p>One of these approaches is the use of inhibitor drugs to block the action of viral proteases, the enzymes that cleave polyproteins encoded in the viral genome to yield several functional proteins. If these proteases are inactivated, the virus cannot synthesize the proteins it requires to reproduce, so inhibiting these enzymes may be an effective way of treating viral diseases. For example, protease inhibitors are key components of highly active antiretroviral therapy (HAART), which renders HIV a chronic disease.</p><p>In the case of SARS-CoV-2, many inhibitor candidates have been identified for its main protease, which is called M<sup>pro</sup> (<xref ref-type="bibr" rid="bib6">Jin et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Narayanan et al., 2022</xref>). One of these inhibitors, with the trade name Paxlovid, has been authorized for emergency use by the United States Federal Drugs Administration (FDA), and pharmacists have been allowed to prescribe it since July 2022 (<xref ref-type="bibr" rid="bib9">Owen et al., 2021</xref>; <xref ref-type="bibr" rid="bib3">FDA, 2022</xref>). But can M<sup>pro</sup> inhibitors be designed to avoid the rapid obsolescence we have observed in vaccines as a result of viral evolution? Now, in eLife, Julia Flynn, Daniel Bolon and colleagues at the University of Massachusetts (UMass) Chan Medical School and the Novartis Institutes for Biomedical Research report the results of experiments assessing the effects of different mutations on the proteolytic activity of M<sup>Pro</sup> (<xref ref-type="bibr" rid="bib4">Flynn et al., 2022</xref>).</p><p>Using a method called deep mutational scanning (<xref ref-type="bibr" rid="bib5">Fowler and Fields, 2014</xref>), Flynn et al. generated a ‘library’ that contained almost every single missense mutation of the M<sup>pro</sup> enzyme relative to the sequence found in the original Wuhan isolate (<xref ref-type="bibr" rid="bib14">Wu et al., 2020</xref>). Missense mutations are changes to a single nucleotide in the sequence that alter the resulting amino acid. Assessing the activity of the M<sup>Pro</sup> variants that result from each conceivable missense mutation revealed how they each affect the activity of the enzyme. To do this, Flynn et al. placed the library into yeast cells, and assessed how well each variant of the protease worked in three different environments.</p><p>The results showed that the proteolytic activity of each variant was correlated across the three assays, implying that the assays capture the same properties of M<sup>Pro</sup>. Flynn et al. also found a correlation between the results of their assays and previous measurements of the catalytic rates for individual variants. Additionally, the vast majority of the 290 missense mutations of M<sup>Pro</sup> observed most frequently (at least 100 times) in COVID-19 patients exhibited activity comparable to that of the wild type. This further confirmed that Flynn et al.’s assay captures the biologically relevant function of the enzyme. Finally, the team found that all of the mutation-intolerant residues in M<sup>Pro</sup> (the sites at which at least 17 out of the 20 alternative amino acids block the protein’s activity) are highly conserved in other coronaviruses. This suggests that inhibitors designed against the current SARS-CoV-2 form of the enzyme will likely be active against future, emergent outbreaks.</p><p>Most protease inhibitors act by competitively occupying the enzyme’s binding pocket to the exclusion of its native substrate. Therefore, Flynn et al. decided to further analyze missense mutations in the vicinity of the binding pocket that nevertheless preserve enzyme activity, reasoning that these mutations might represent opportunities for the virus to evolve resistance to inhibitors. Unfortunately, they found that mutations at many of those residues preserve the proteolytic ability of M<sup>pro</sup> (<xref ref-type="bibr" rid="bib2">Cho et al., 2021</xref>).</p><p>Similarly, and perhaps of more immediate concern, Flynn et al. identified three missense mutations that reduced the binding stability to Paxlovid by at least 1 kcal/mol, corresponding to an approximately five-fold reduction in the drug’s binding affinity, while maintaining proteolytic activity. These represent likely resistance mutations; indeed, a subset of these mutations have now been observed in laboratory populations of SARS-CoV-2 challenged with this version of Paxlovid, as well as in currently circulating isolates (<xref ref-type="bibr" rid="bib10">Service, 2022</xref>). It will be important to monitor the frequency of these three mutations in patients being treated with Paxlovid as its use becomes more widespread.</p><p>But the potential implications of the findings of Flynn et al. go further than providing insight into prospects for resistance evolution against existing M<sup>pro</sup> inhibitors. Some years ago, the notion of the ‘substrate envelope’ of a viral protease – the overlapping volume occupied by all of its native substrates – was introduced (<xref ref-type="bibr" rid="bib7">King et al., 2004</xref>). The inspiration was that the substrate specificity of the HIV protease seemed to be determined by the shape of the substrate rather than by a specific amino acid sequence. Because resistance mutations must allow an enzyme to distinguish between its inhibitors and its substrates, they might work by introducing atomic overlaps or disfavored electrostatics in the region where the inhibitor protrudes beyond the substrate envelope. In a recent companion study, researchers at UMass and Novartis (including many authors from Flynn et al.) have reported a high-resolution structure of the SARS-CoV-2 M<sup>pro</sup> substrate envelope (<xref ref-type="bibr" rid="bib11">Shaqra et al., 2022</xref>).</p><p>Together, these two articles provide clear guidance for the development of evolution-resistant protease inhibitors against SARS-CoV-2. To find clinically durable candidates, compounds should be screened first to identify those that lie entirely within the enzyme’s substrate envelope. Of these, care should be taken to select those that interact with one or more mutation-intolerant residues. This will make it more difficult for the protease to evolve the ability to discriminate between its native substrates and the drug without blocking its activity. Of course, Darwinian evolution is a tremendously powerful force, and resistance has evolved against every antimicrobial class ever deployed in the clinic. Nevertheless, the functional and structural resolution now available for M<sup>pro</sup>-inhibitors offers new optimism 30 months into the COVID-19 pandemic.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Beyond Omicron: what’s next for SARS-CoV-2 evolution?</article-title><source>Nature</source><volume>600</volume><fpage>204</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-03619-8</pub-id><pub-id pub-id-type="pmid">34876665</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>E</given-names></name><name><surname>Rosa</surname><given-names>M</given-names></name><name><surname>Anjum</surname><given-names>R</given-names></name><name><surname>Mehmood</surname><given-names>S</given-names></name><name><surname>Soban</surname><given-names>M</given-names></name><name><surname>Mujtaba</surname><given-names>M</given-names></name><name><surname>Bux</surname><given-names>K</given-names></name><name><surname>Moin</surname><given-names>ST</given-names></name><name><surname>Tanweer</surname><given-names>M</given-names></name><name><surname>Dantu</surname><given-names>S</given-names></name><name><surname>Pandini</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Ramanathan</surname><given-names>A</given-names></name><name><surname>Islam</surname><given-names>B</given-names></name><name><surname>Mey</surname><given-names>A</given-names></name><name><surname>Bhowmik</surname><given-names>D</given-names></name><name><surname>Haider</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dynamic profiling of β-coronavirus 3CL M<sup>pro</sup> protease ligand-binding sites</article-title><source>Journal of Chemical Information and Modeling</source><volume>61</volume><fpage>3058</fpage><lpage>3073</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00449</pub-id><pub-id pub-id-type="pmid">34124899</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="web"><person-group person-group-type="author"><collab>FDA</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Coronavirus (COVID-19) Update: FDA authorizes pharmacists to prescribe Paxlovid with certain limitations</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations</ext-link><date-in-citation iso-8601-date="2022-07-09">July 9, 2022</date-in-citation></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JM</given-names></name><name><surname>Samant</surname><given-names>N</given-names></name><name><surname>Schneider-Nachum</surname><given-names>G</given-names></name><name><surname>Bakan</surname><given-names>DT</given-names></name><name><surname>Yilmaz</surname><given-names>NK</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name><name><surname>Moquin</surname><given-names>SA</given-names></name><name><surname>Dovala</surname><given-names>D</given-names></name><name><surname>Bolon</surname><given-names>DNA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Comprehensive fitness landscape of SARS-CoV-2 M<sup>pro</sup> reveals insights into viral resistance mechanisms</article-title><source>eLife</source><volume>11</volume><elocation-id>e77433</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.77433</pub-id><pub-id pub-id-type="pmid">35723575</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>DM</given-names></name><name><surname>Fields</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Deep mutational scanning: a new style of protein science</article-title><source>Nature Methods</source><volume>11</volume><fpage>801</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3027</pub-id><pub-id pub-id-type="pmid">25075907</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>You</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Guddat</surname><given-names>LW</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of M<sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors</article-title><source>Nature</source><volume>582</volume><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id><pub-id pub-id-type="pmid">32272481</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>NM</given-names></name><name><surname>Prabu-Jeyabalan</surname><given-names>M</given-names></name><name><surname>Nalivaika</surname><given-names>EA</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Combating susceptibility to drug resistance: lessons from HIV-1 protease</article-title><source>Chemistry &amp; Biology</source><volume>11</volume><fpage>1333</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2004.08.010</pub-id><pub-id pub-id-type="pmid">15489160</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>A</given-names></name><name><surname>Narwal</surname><given-names>M</given-names></name><name><surname>Majowicz</surname><given-names>SA</given-names></name><name><surname>Varricchio</surname><given-names>C</given-names></name><name><surname>Toner</surname><given-names>SA</given-names></name><name><surname>Ballatore</surname><given-names>C</given-names></name><name><surname>Brancale</surname><given-names>A</given-names></name><name><surname>Murakami</surname><given-names>KS</given-names></name><name><surname>Jose</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>169</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03090-9</pub-id><pub-id pub-id-type="pmid">35217718</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>DR</given-names></name><name><surname>Allerton</surname><given-names>CMN</given-names></name><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Aschenbrenner</surname><given-names>L</given-names></name><name><surname>Avery</surname><given-names>M</given-names></name><name><surname>Berritt</surname><given-names>S</given-names></name><name><surname>Boras</surname><given-names>B</given-names></name><name><surname>Cardin</surname><given-names>RD</given-names></name><name><surname>Carlo</surname><given-names>A</given-names></name><name><surname>Coffman</surname><given-names>KJ</given-names></name><name><surname>Dantonio</surname><given-names>A</given-names></name><name><surname>Di</surname><given-names>L</given-names></name><name><surname>Eng</surname><given-names>H</given-names></name><name><surname>Ferre</surname><given-names>R</given-names></name><name><surname>Gajiwala</surname><given-names>KS</given-names></name><name><surname>Gibson</surname><given-names>SA</given-names></name><name><surname>Greasley</surname><given-names>SE</given-names></name><name><surname>Hurst</surname><given-names>BL</given-names></name><name><surname>Kadar</surname><given-names>EP</given-names></name><name><surname>Kalgutkar</surname><given-names>AS</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Mason</surname><given-names>SW</given-names></name><name><surname>Noell</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>JJ</given-names></name><name><surname>Obach</surname><given-names>RS</given-names></name><name><surname>Ogilvie</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>NC</given-names></name><name><surname>Pettersson</surname><given-names>M</given-names></name><name><surname>Rai</surname><given-names>DK</given-names></name><name><surname>Reese</surname><given-names>MR</given-names></name><name><surname>Sammons</surname><given-names>MF</given-names></name><name><surname>Sathish</surname><given-names>JG</given-names></name><name><surname>Singh</surname><given-names>RSP</given-names></name><name><surname>Steppan</surname><given-names>CM</given-names></name><name><surname>Stewart</surname><given-names>AE</given-names></name><name><surname>Tuttle</surname><given-names>JB</given-names></name><name><surname>Updyke</surname><given-names>L</given-names></name><name><surname>Verhoest</surname><given-names>PR</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19</article-title><source>Science</source><volume>374</volume><fpage>1586</fpage><lpage>1593</lpage><pub-id pub-id-type="doi">10.1126/science.abl4784</pub-id><pub-id pub-id-type="pmid">34726479</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Service</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug</article-title><source>Science</source><volume>377</volume><fpage>138</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1126/science.add7226</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaqra</surname><given-names>AM</given-names></name><name><surname>Zvornicanin</surname><given-names>SN</given-names></name><name><surname>Huang</surname><given-names>QYJ</given-names></name><name><surname>Lockbaum</surname><given-names>GJ</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><name><surname>Tandeske</surname><given-names>L</given-names></name><name><surname>Bakan</surname><given-names>DT</given-names></name><name><surname>Flynn</surname><given-names>J</given-names></name><name><surname>Bolon</surname><given-names>DNA</given-names></name><name><surname>Moquin</surname><given-names>S</given-names></name><name><surname>Dovala</surname><given-names>D</given-names></name><name><surname>Kurt Yilmaz</surname><given-names>N</given-names></name><name><surname>Schiffer</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>3556</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31210-w</pub-id><pub-id pub-id-type="pmid">35729165</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>New versions of Omicron are masters of immune evasion</article-title><source>Science</source><volume>376</volume><fpage>679</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1126/science.adc9473</pub-id><pub-id pub-id-type="pmid">35549399</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><year iso-8601-date="2022">2022</year><article-title>WHO Coronavirus (COVID-19) Dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link><date-in-citation iso-8601-date="2022-07-06">July 6, 2022</date-in-citation></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>Y-M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Song</surname><given-names>Z-G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>Z-W</given-names></name><name><surname>Tian</surname><given-names>J-H</given-names></name><name><surname>Pei</surname><given-names>Y-Y</given-names></name><name><surname>Yuan</surname><given-names>M-L</given-names></name><name><surname>Zhang</surname><given-names>Y-L</given-names></name><name><surname>Dai</surname><given-names>F-H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q-M</given-names></name><name><surname>Zheng</surname><given-names>J-J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>EC</given-names></name><name><surname>Zhang</surname><given-names>Y-Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref></ref-list></back></article>